New data demonstrate significant fat mass loss
while preserving lean mass
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to
ending obesity, today announced three scientific presentations at
the 31st European Congress on Obesity (ECO) held in Venice, Italy,
on 12-15 May, 2024.
Presentations include data from a study of 712 patients treated
with the Allurion Program, which is anchored by the Allurion
Balloon and enhanced by the Virtual Care Suite featuring Allurion’s
proprietary behavior change program. This study was conducted at
six obesity centers in six countries, and the data showed patients
achieved total body weight loss (TBWL) of 14.1% on average at 4
months, 70% of which came from fat mass and only 30% of which came
from lean body mass.
“The Allurion Program was designed to monitor both weight loss
and lean body mass, facilitate basic changes in behavior that can
protect skeletal muscle, and reduce the impact on lean body mass
during periods of rapid weight loss,” said Dr. Shantanu Gaur,
Founder and CEO of Allurion. “Research shows that preserving lean
body mass while losing weight is critical to maintaining metabolic
health and achieving positive, sustained outcomes.”
Existing obesity interventions — including anti-obesity
medications such as GLP-1s and bariatric surgery — are often not
delivered with coaching or behavior change programs designed to
protect lean body mass, which can lead to significant reductions in
muscle mass. For example, GLP-1s have been shown to lead to
approximately 40% lean body mass loss at one year of
treatment.1,2
“Maintaining lean body mass in the setting of significant
caloric deficit is a challenge. We believe the Allurion Program
makes this possible with its body composition monitoring and a
personalized program that focuses on outcomes beyond just weight,”
said Dr. Ram Chuttani, Chief Medical Officer of Allurion. “We will
continue to partner with Allurion Program providers to help them
optimize their patient outcomes through our training, support, and
digital health platform.”
With more intensive programs, early data indicate that muscle
mass loss can be avoided entirely. In a previous similar, but
smaller, study of a highly intensive multidisciplinary Allurion
Program with weekly follow up, patients achieved 14.6% TBWL at 4
months, and their lean body mass actually increased, with 100% of
the weight loss derived from fat mass.3
“These results indicate that the Allurion Program may be more
protective of muscle mass during weight loss than alternative
methods,” continued Gaur. “I am looking forward to exploring how we
can leverage the Allurion Virtual Care Suite and Coach Iris to
deliver an even more personalized and intensive coaching program to
our patients and potentially eliminate muscle mass loss entirely
without significant human intervention.”
Presentations at ECO also include data on the positive impact of
a behavior change coaching skills course developed by Allurion and
the positive impact of GLP-1s on the Allurion Program.
Details of the presentations are as follows:
Title: Body Composition Changes during the Swallowable,
Non-Endoscopic Gastric Balloon Program (SIGBP): Prioritizing Lean
Mass Preservation for Sustainable, Healthy Weight Loss
Presenter: Roberta Ienca, M.D., Weight Management Center,
Nuova Villa Claudia Clinic
Title: Training HCPs in behavior change coaching skills
improves weight loss outcomes of the Swallowable, Non-Endoscopic
Gastric Balloon Program Presenter: Zoe Griffiths, Bsc,. RD,
Senior Director Behavioral Medicine, Allurion
Title: The Anti-Obesity Medication Halo Effect: Rising
Interest in Medications Drives Increased Awareness and Uptake of
Other Medical Obesity Treatments Presenter: Zoe Griffiths,
Bsc,. RD, Senior Director Behavioral Medicine, Allurion
For more information about ECO 2024, please visit:
https://eco2024.org/.
Sources: 1. Wilding JPH, Batterham RL, Calanna S, et al. N Engl
J Med. 2021;384(11):989-1002. 2. McCrimmon RJ, Catarig AM, Frias
JP, et al. Diabetologia. 2020;63(3):473-485. 3. Raftopoulos and
Giannakou. Surg for Obes and Rel Dis. 2017;13:1174-1182.
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is
a weight loss platform that features the Allurion Gastric Balloon,
the world’s first and only swallowable, procedure-less intragastric
balloon for weight loss, and offers access to the Allurion Virtual
Care Suite, including the Allurion Mobile App for consumers,
Allurion Insights for health care providers featuring the Coach
Iris AI Platform, and the Allurion Connected Scale. The Allurion
Virtual Care Suite is also available to providers separately from
the Allurion Program to help customize, monitor and manage weight
loss therapy for patients regardless of their treatment plan:
gastric balloon, surgical, medical or nutritional. The Allurion
Gastric Balloon is an investigational device in the United
States.
For more information about Allurion and the Allurion Virtual
Care Suite, please visit www.allurion.com.
Allurion is a trademark of Allurion Technologies, Inc. in the
United States and countries around the world.
Forward-Looking Statements
This press release may contain certain forward-looking
statements within the meaning of the U.S. federal and state
securities laws. These forward-looking statements generally are
identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions and
include statements regarding the ability of the Allurion Program,
including the VCS, to improve patient and clinical outcomes,
including outcome improvements over time, the impact of a behavior
change coaching skills course, and the impact of gLP-1s on the
Allurion Program. Forward-looking statements are predictions,
projections and other statements about future events that reflect
the current beliefs and assumptions of Allurion’s management based
on information currently available to them and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future results or developments to differ materially from the
forward-looking statements in this communication, including but not
limited to (i) the ability of Allurion to obtain and maintain
regulatory approvals for and successfully commercialize the
Allurion Program, including the Allurion Balloon and the VCS, (ii)
the timing of, and results from, our clinical studies and trials,
(iii) the evolution of the markets in which Allurion competes, (iv)
the ability of Allurion to defend its intellectual property, (v)
the impact of the COVID-19 pandemic, the Russia and Ukraine war,
and the Israel-Hamas conflict on Allurion’s business, (vi)
Allurion’s expectations regarding its market opportunities,
including those for the VCS platform, and (vii) the risk of
economic downturns and a changing regulatory landscape in the
highly competitive industry in which Allurion operates. The
foregoing list of factors is not exhaustive. You should carefully
consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of Allurion’s
Annual Report on Form 10-K filed on March 26, 2024 (as subsequently
amended) and other documents filed by Allurion from time to time
with the U.S. Securities and Exchange Commission. These filings
identify and address other important risks and uncertainties that
could cause actual events and results to differ materially from
those contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Allurion assumes no obligation and does not intend to update or
revise these forward-looking statements, whether as a result of new
information, future events, or otherwise. Allurion does not give
any assurance that it will achieve its expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240515859813/en/
Global Media: Cedric Damour PR Manager +33 7 84 21 02 20
cdamour@allurion.com
Investors: Mike Cavanaugh, Investor Relations ICR
Westwicke (617) 877-9641 mike.cavanaugh@westwicke.com
Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Nov 2024 to Dec 2024
Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Dec 2023 to Dec 2024